地芬辛-D4 | 35607-36-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 地芬辛-D4
• 中文别名: 1-(3-氰基-3,3-二苯基丙基)-4-苯基哌啶-4-羧酸单盐酸盐
• 英文名称: Difenoxin hydrochloride
• 英文别名: 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylic acid;hydrochloride
• CAS: 35607-36-4
• 化学式: C28H29ClN2O2
• 分子量: 461.0
• InChiKey: VMIZTXDGZPTKIK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.59
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  65.5
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS<br/>[FR] ADMINISTRATION CIBLÉE D'UN MÉDICAMENT FAISANT APPEL À DES COUPLEURS FONDÉS SUR L'AFFINITÉ
  申请人：INVICTUS ONCOLOGY PVT LTD

  公开号：WO2015148126A1

  公开（公告）日：2015-10-01

  The current invention discloses targeted drug delivery conjugates comprising a targeting moiety linked to a drug via a molecule having an affinity for the targeting moiety. Typically, the conjugate comprises a targeting ligand and a molecule of interest, e.g., a therapeutic agent. The targeting ligand and the molecule of interest are linked to each other via an affinity ligand. The affinity ligand is further covalently or non-covalently linked to a drug or therapeutic agent. The drug can be modified to make it more soluble and so that it cleaves from the linking molecule at the target site.

  当前的发明揭示了包括通过具有与靶向基团亲和力的分子连接到药物的靶向药物传递共轭物。通常，该共轭物包括一个靶向配体和一个感兴趣的分子，例如，一个治疗剂。靶向配体和感兴趣的分子通过一个亲和配体相互连接。该亲和配体进一步以共价或非共价方式连接到药物或治疗剂。药物可以被修改以使其更溶解，并使其在靶点处从连接分子中解离。
• [EN] 3-AMINO-4H-BENZO[E][1,2,4]THIADIAZINE 1,1-DIOXIDE DERIVATIVES AS INHIBITORS OF MRGX2<br/>[FR] DÉRIVÉS DE 1,1-DIOXYDE DE 3-AMINO-4H-BENZO[E][1,2,4]THIADIAZINE EN TANT QU'INHIBITEURS DE MRGX2
  申请人：SOLENT THERAPEUTICS LLC

  公开号：WO2020223255A1

  公开（公告）日：2020-11-05

  Disclosed are compounds of Formula (1), tautomers thereof, and pharmaceutically acceptable salts of the compounds or tautomers, wherein L, R1, R2, R3, R4 and R5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders or conditions associated with MRGX2.

  本公开涉及Formula (1)的化合物及其互变异构体，以及这些化合物或互变异构体的药用可接受盐，其中L、R1、R2、R3、R4和R5在说明书中有定义。本公开还涉及制备Formula (1)化合物的材料和方法，含有这些化合物的药物组合物，以及它们用于治疗与MRGX2相关的疾病、疾患或症状的用途。
• (S)-N-Stereoisomers of 7,8-Saturated-4,5-Epoxy-Morphinanium Analogs
  申请人：Perez Julio

  公开号：US20080207669A1

  公开（公告）日：2008-08-28

  Novel (S)-N-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs are disclosed. Pharmaceutical compositions containing the (S)-N-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs and methods for their pharmaceutical uses are also disclosed. Such analogs are disclosed as being useful in treating, among varying conditions, hypermotility of the gastrointestinal tract.

  本专利揭示了7,8-饱和-4,5-环氧-吗啡盐类的（S）-N-立体异构体。还揭示了含有7,8-饱和-4,5-环氧-吗啡盐类（S）-N-立体异构体的药物组合物，以及其药用方法。这些类似物被发现可用于治疗多种情况，包括胃肠道过度运动。
• LINEAR POLYESTER AND SEMI-LINEAR GLYCIDOL POLYMER SYSTEMS: FORMULATION AND SYNTHESIS OF NOVEL MONOMERS AND MACROMOLECULAR STRUCTURES
  申请人：Vanderbilt University

  公开号：US20140005278A1

  公开（公告）日：2014-01-02

  Disclosed herein are glycidol-based polymers, nanoparticles, and methods related thereto useful for drug delivery. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本文公开了基于环氧丙烷醇的聚合物、纳米粒子及相关的药物传递方法，本摘要旨在作为特定领域搜索的扫描工具，不应限制本发明。
• Aqueous polyglycidol synthesis with ultra-low branching
  申请人：Vanderbilt University

  公开号：US10308763B2

  公开（公告）日：2019-06-04

  Disclosed herein are glycidol-based polymers, nanoparticles, and methods related thereto useful for a variety of applications, including, but not limited to, drug delivery. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本文披露了基于环氧丙烷醇的聚合物、纳米粒子及相关方法，可用于各种应用，包括但不限于药物输送。本摘要旨在作为特定领域搜索的扫描工具，不旨在限制本发明。